You are here
Thorium dioxide (Thorotrast)
Acute myeloid leukaemia - Thorium dioxide (Thorotrast) Factor
Last reviewed for CCPS 08 January 2007.
Preliminary questions [36771]
36772 there is some evidence that thorium dioxide (Thorotrast) may be a factor in the development of the condition under consideration.
36773 the veteran has received thorium dioxide (Thorotrast) at some time.
36774 — the veteran has established the causal connection between thorium dioxide (Thorotrast) and VEA service for the clinical onset of acute myeloid leukaemia.
36776 — the veteran has established the causal connection between thorium dioxide (Thorotrast) and eligible service for the clinical onset of acute myeloid leukaemia.
or
36775 — the veteran has established the causal connection between thorium dioxide (Thorotrast) and operational service for the clinical onset of acute myeloid leukaemia.
Clinical onset and operational service [36775]
36777 the veteran received thorium dioxide (Thorotrast) at least one year before the clinical onset of the condition under consideration. 36779 — the veteran received thorium dioxide (Thorotrast) for an illness or injury which is identifiable. 36782 — the identified illness or injury, for which the veteran received thorium dioxide (Thorotrast), is causally related to operational service. Clinical onset and eligible service [36776] 36779 — the veteran received thorium dioxide (Thorotrast) for an illness or injury which is identifiable.
36783 — the identified illness or injury, for which the veteran received thorium dioxide (Thorotrast), is causally related to eligible service.